Treatment
Atezolizumab & Bevacizumab clinical trials
We’re tracking 70 recruiting studies that include Atezolizumab & Bevacizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07157969RecruitingPhase 2
Immunotherapy and anti-VEGF with or without local therapy for liver cancer
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
BeijingAges 18 years+ - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
Berkeley, CaliforniaAges 18 years+ - NCT07293468RecruitingPhase 2/Phase 3
Comparing two treatments for advanced liver cancer
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hong KongAges 18–80 - NCT04224636RecruitingPhase 2
Atezolizumab and bevacizumab with optional repeat chemo liver procedure
This Phase 2 trial tests whether starting with atezolizumab plus bevacizumab, then using an on-demand TACE (a targeted liver artery chemo treatment) can control hepatocellular carcinoma (liver cancer). It also compares this approach to giving both medicines together with an initial TACE right away, aiming to improve tumor control and outcomes.
BonnAges 18 years+ - NCT06823375RecruitingPhase 2
Radiation plus immunotherapy for liver cancer with major vein clot
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
Hong KongAges 18 years+ - NCT06595108Recruiting
Targeted therapy and radiation for advanced liver cancer
This trial tests a combination of immunotherapy (atezolizumab), targeted therapy (bevacizumab), and targeted radiation for advanced liver cancer that cannot be surgically removed. The goal is to see if this approach helps control the cancer.
Yongin-siAges 19–80 - NCT07010497RecruitingPhase 2
Study of a three-drug combo for advanced liver cancer
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
SeoulAges 19 years+ - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Birmingham, AlabamaAges 18 years+ - NCT05488522RecruitingPhase 1
Radiation plus immunotherapy for liver cancer
This early-phase trial tests a treatment plan that combines focused radiation with two medicines—an immunotherapy drug and an anti-angiogenesis drug—to treat hepatocellular carcinoma (liver cancer). It may help shrink tumors or control disease when surgery or ablation can’t be used, and when systemic (whole-body) treatment is needed.
Philadelphia, PennsylvaniaAges 18–99 - NCT05620771RecruitingPhase 2
Y-90 radioembolization plus treatment for high-risk liver cancer
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Chicago, IllinoisAges 18 years+ - NCT05984511Recruiting
Combined treatment for liver cancer with portal vein tumor thrombus
This trial tests whether adding immunotherapy (atezolizumab/bevacizumab) and a type of internal radiation (I-125 seeds) to standard chemoembolization (TACE) can help people with liver cancer that has spread into the main liver blood vessel (portal vein). It aims to control the tumor and improve outcomes.
Guangzhou, GuangzhouAges 18–75 - NCT06605664RecruitingPhase 2
New MRI scan for liver cancer with radiation and immunotherapy
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
Taoyuan CityAges 18 years+ - NCT06961526Recruiting
Preventing varices bleeding in liver cancer patients on immunotherapy
This trial tests if preventing esophageal varices (swollen veins in the food pipe) can reduce bleeding risk in people with advanced liver cancer who are receiving a combination of two drugs (atezolizumab and bevacizumab). It may help those with good liver function and no high-risk varices at the start.
Tanta, GharbyeaAges 18 years+ - NCT07091942Recruiting
Curative therapy after Atezo-Bev for advanced liver cancer
This trial is for people with liver cancer who have already been treated with Atezo-Bev (a combination of atezolizumab and bevacizumab) and whose tumors have shrunk significantly. The goal is to see if further curative treatments can be used to improve outcomes.
Taipei, SelectAges Any age - NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+ - NCT07610551Recruiting
Combination therapy for advanced liver cancer
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
Xi’an, ShanxiAges 18 years+ - NCT07088081Enrolling by invitation
Immunotherapy drugs for advanced liver cancer
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
Cairo, AbbasyaAges 18 years+ - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Stanford, CaliforniaAges 18 years+ - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Duarte, CaliforniaAges 18 years+ - NCT05588388RecruitingPhase 2
Testing bevacizumab with chemo and immunotherapy for small cell lung cancer
This Phase 2 trial studies whether adding bevacizumab to chemo plus immunotherapy (including atezolizumab) can improve outcomes in extensive-stage small cell lung cancer (ES-SCLC) that has spread to the liver. It may help by blocking tumor blood vessel growth while boosting anti-cancer immune and treatment effects.
Los Angeles, CaliforniaAges Any age - NCT05525858Recruiting
Genomic testing–guided treatment for advanced solid tumors
This study uses your tumor’s genetic test results to help match you to the most suitable treatment when standard options have failed or don’t exist. It may help by targeting therapies based on specific gene changes found in your cancer.
Bucheon-siAges 19 years+ - NCT05441475Enrolling by invitationPhase 2
Trial for advanced liver cancer using ABSK-011 plus atezolizumab
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
Hubei, Shanghai MunicipalityAges 18 years+
Common questions
- Are there clinical trials studying Atezolizumab & Bevacizumab?
- Yes. Clin2 currently lists 70 recruiting studies that include Atezolizumab & Bevacizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Atezolizumab & Bevacizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Atezolizumab & Bevacizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Atezolizumab & Bevacizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.